← Back to Search

Genetic Testing

Single Cohort for Neurological Disorders (NeuroSEQ Trial)

N/A

Waitlist Available

Research Sponsored by Illumina, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 365

Awards & highlights

NeuroSEQ Trial Summary

This trial will evaluate how effective a whole genome sequencing test is for diagnosing neurological disorders in adults, compared to the standard of care tests.

Eligible Conditions

Neurological Disorders
Neurological Deficits

NeuroSEQ Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 365

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 365

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 365 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Diagnostic Yield between cWGS and SOC testing

Secondary outcome measures

Change of Management between cWGS and SOC testing as measured by a management questionnaire collected on a case report form

Diagnostic Accuracy between cWGS and SOC testing when comparing the medical monitor test outcome and the site PI test outcome

Diagnostic Yield within Cohort when evaluating specific Neurologic disorders

+2 more

Other outcome measures

Clinical Survey by the clinician who ordered SOC testing

Participant Survey

Time to Diagnosis between cWGS and SOC testing

NeuroSEQ Trial Design

1Treatment groups

Experimental Treatment

Group I: Single CohortExperimental Treatment1 Intervention

All participants will receive cWGS testing revealed to the site PI/clinician at Day 180. Participants will all receive standard of care testing throughout the study.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Illumina, Inc.Lead Sponsor

24 Previous Clinical Trials

154,296 Total Patients Enrolled

Ryan J Taft, Ph.DStudy ChairIllumina, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the current enrollment period still open for this investigation?

"According to info available on clinicaltrials.gov, this medical experiment is actively searching for participants as of October 22nd 2021. It was originally posted in November 18th 2019."

Answered by AI

To what extent is this medical experiment examining patient numbers?

"Affirmative. Clinicaltrials.gov provides evidence that this medical trial, which was initially announced on November 18th 2019, is presently seeking participants. The research necessitates the enrollment of 100 subjects from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology

2019. "NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04170985.